Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus DURAGESIC 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus DURAGESIC 25.
BELBUCA vs DURAGESIC-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic